We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    VAC52150EBL2001
Previous Study | Return to List | Next Study

A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02416453
First Posted: April 15, 2015
Last Update Posted: October 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.
  Purpose
The purpose of this study is to evaluate the safety and tolerability of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as heterologous prime-boost regimens.

Condition Intervention Phase
Healthy Biological: MVA-BN-Filo Biological: Ad26.ZEBOV Biological: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in Europe

Resource links provided by NLM:


Further study details as provided by Janssen Vaccines & Prevention B.V.:

Primary Outcome Measures:
  • Number of Participants With Adverse Events [ Time Frame: Up to 42-day post-boost visit (Day 71 for Group 1; Day 99 for Group 2; or Day 127 for Group 3) ]
  • Number of Participants With Serious Adverse Events [ Time Frame: Up to the end of study (day 365) ]
  • Number of Participants with Reactogenicity (that is, Solicited Local and Systemic Adverse Events) [ Time Frame: Up to 1 week after each study vaccine administration ]

Secondary Outcome Measures:
  • Immune Responses to the Study Vaccine Regimens Measured by an Enzyme-linked Immunosorbent Assay (ELISA) [ Time Frame: At 21-days post boost (Day 50 for Group 1; Day 78 for Group 2; or Day 106 for Group 3) ]

Enrollment: 408
Actual Study Start Date: June 15, 2015
Estimated Study Completion Date: November 17, 2017
Estimated Primary Completion Date: November 17, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
Biological: MVA-BN-Filo
One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
Biological: Ad26.ZEBOV
One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
Biological: Placebo
One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
Experimental: Group 2
Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
Biological: MVA-BN-Filo
One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
Biological: Ad26.ZEBOV
One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
Biological: Placebo
One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
Experimental: Group 3
Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
Biological: MVA-BN-Filo
One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
Biological: Ad26.ZEBOV
One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
Biological: Placebo
One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.

Detailed Description:
This is a randomized, observer-blind, placebo-controlled, parallel-group, multicenter, Phase 2 study evaluating the safety, tolerability and immunogenicity of 3 heterologous prime-boost regimens using Ad26.ZEBOV and MVA-BN-Filo administered to healthy adults participants in Europe. The study consists of a screening period of up to 12 weeks, a vaccination period in which participants will be vaccinated at baseline (Day 1), followed by a boost vaccination on Days 29, 57 or 85, and a post-vaccination phase until 6 month post-boost visit (Days 209, 237 or 265). After unblinding, only participants who received Ad26.ZEBOV and/or MVA-BN-Filo will continue the study until the Day 365 (or until the start of the roll-over study or for an additional 12 months [whichever comes first] for participants in France who agree to continue the long-term follow-up after Day 365) visit to assess long-term safety and immunogenicity. Participants will enroll into 3 cohorts: that is, Cohort 1(Participants will receive Ad26.ZEBOV and MVA-BN-Filo in an open-label fashion), Cohort 2 (Participants will be randomized to receive the prime-boost vaccination with either Ad26.ZEBOV followed by MVA-BN-Filo, or placebo in a 14:1 ratio) and Cohort 3 (Participants will be randomized to receive the prime-boost vaccination with either Ad26.ZEBOV followed by MVA-BN-Filo, or placebo in a 10:3 ratio). In Cohorts 2 and 3, core immunogenicity assessments (humoral and cellular assays) will be performed. In Cohort 2, additional immunogenicity assessments will be done. In Cohort 1, plasma blast response kinetics will be evaluated. Safety will be monitored during the study.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be healthy in the Investigator's clinical judgment on the basis of medical history, physical examination, electrocardiogram (ECG) and vital signs performed at Screening
  • Must be healthy on the basis of clinical laboratory tests performed at Screening. If the results of the laboratory screening tests are outside the normal reference ranges, the participant may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study
  • Before randomization, a woman must be either of childbearing potential and practicing (or intending to practice) a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies, beginning at least 28 days prior to vaccination OR not of childbearing potential: postmenopausal (greater than [>] 45 years of age with amenorrhea for at least 2 years or lesser than or equal to [<=] 45 years of age with amenorrhea for at least 6 months, and a serum follicle stimulating hormone (FSH) level >40 international unit per milliliter [IU/L]); permanently sterilized (for example, bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy
  • Woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine beta-hCG pregnancy test immediately prior to each study vaccine administration
  • Man who is sexually active with a woman of childbearing potential and has not had a vasectomy performed more than 1 year prior to screening must be willing to use condoms for sexual intercourse beginning prior to enrollment

Exclusion Criteria:

  • Having received any candidate Ebola vaccine
  • Diagnosed with Ebola virus disease, or prior exposure to Ebola virus, including travel to West Africa less than 1 month prior to screening. West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone
  • Having received any experimental candidate adenovirus serotype 26 (vector: Ad26) or Modified Vaccinia Ankara (MVA-) based vaccine in the past
  • Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines including known allergy to egg, egg products and aminoglycosides
  • Presence of acute illness or temperature greater than or equal to 38.0 C on Day 1
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02416453


Locations
France
Creteil, France
Marseille, France
Paris, France
Pierre Benite, France
Rennes, France
Saint Etienne, France
Strasbourg, France
Tours, France
United Kingdom
London, United Kingdom
Oxford, United Kingdom
Southampton, United Kingdom
Sponsors and Collaborators
Janssen Vaccines & Prevention B.V.
Investigators
Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial Janssen Vaccines & Prevention B.V.
Study Director: Inserm Clinical Trials Institut National de la Santé Et de la Recherche Médicale, France
  More Information

Responsible Party: Janssen Vaccines & Prevention B.V.
ClinicalTrials.gov Identifier: NCT02416453     History of Changes
Other Study ID Numbers: CR107227
VAC52150EBL2001 ( Other Identifier: Janssen Vaccines & Prevention B.V. )
2015-000596-27 ( EudraCT Number )
First Submitted: April 10, 2015
First Posted: April 15, 2015
Last Update Posted: October 3, 2017
Last Verified: October 2017

Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Janssen Vaccines & Prevention B.V.:
Healthy
Ebola viruses
Ebola Viral Disease (EVD)
Filoviruses
Monovalent vaccine
Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo)
Safety
Immunogenicity

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs